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Biomedical EngineeringThe future is digital: In silico tissue engineering
Liesbet Geris1,2,3, Toon Lambrechts2,4, Aurélie Carlier5 and
Ioannis Papantoniou2,6Abstract
The Industry 4.0 concept refers to automation and data ex-
change in manufacturing technologies, which includes tech-
nologies for cell therapy product manufacturing. An important
aspect of this concept is the development and use of Digital
Twins. A Digital Twin is a digital representation of a product or
process that is used to optimize the design and use of said
product or process. In this opinion article, we show that such
Digital Twins have already been developed for a variety of
tissue engineering processes. Using skeletal tissue engineer-
ing as a case study, we discuss a number of models at various
stages of use between bench and bedside and ranging from
pure data-driven models to models built on known mecha-
nisms and first principles. Finally, we emphasize the impor-
tance of data collection and model validation to ensure,
amongst others, compliance to regulatory guidelines.Addresses
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Having entered the 4th phase of the industrial revolu-
tion, so-called Industry 4.0 or smart industry, automa-
tion and data exchange have become crucial concepts in
modern manufacturing technologies [1]. Industry 4.0
creates a ‘smart factory’ and within such factories, cyber-
physical systems monitor physical processes, creating a
virtual copy of the physical world that subsequently can
be used to make decentralized decisions. These cyber-
physical systems communicate and cooperate with one
another and with humans via the ‘Internet of Things’
and cloud computing. In the context of Industry 4.0,
another engineering concept that has been around for 30
odd years in the engineering community, that of the
‘Digital Twin’, is receiving renewed attention. Whereas
originally, the Digital Twin referred to a static repre-
sentation of physical objects by means of 3D computer
models (Computer Aided Design & Manufacturing
CAD-CAM), it has extended now to representations of
4D dynamic systems ranging from tiny sensors to huge
Boeing 777s and from cars to power plants. The Digital
Twin concept provides the engineering community with
a way to handle increasing complexity in the design,
manufacturing, control and maintenance of objects,
systems and processes, which makes it a crucial element
for the implementation of the Industry 4.0 concept.
This renewed attention for the concept has even lead to
it being listed it on Gartner’s Top 10 list of Strategic
Technology Trends for 2017 as well as 2018 [2].
Industry 4.0 is by no means restricted to classical engi-
neering industries. On the contrary, many biotech
companies are already fully committed. Nevertheless, in
regenerative medicine there is still substantial progress
to be made. Cell-based therapies have often been
presented as potential major growth drivers of the global
economy. With a record number of ongoing clinical trials,
the field has emerged from the ‘valley of death’ it went
through in the late ‘90s, a period that is typical for new
emerging technologies that are hyped beyond what they
are able to deliver at that stage. One of the major bot-
tlenecks and cost drivers at this point is the
manufacturing process that all too often is a scaled out
version of the cumbersome manual laboratory proced-
ures established during the development phase.
Embracing the concepts of process engineering that
since long are being used in biopharmaceuticalwww.sciencedirect.com
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would allow the field to increase product quality and
productivity, decrease cost and increase the (economic)
viability of the products.
As mentioned above, one of the important steps in
order to fully embrace the Industry 4.0 concept is the
development of Digital Twins. The complexity
required from a Digital Twin will vary based on the use
case and the business objective. Whereas in certain
situations Digital Twins can be as simple as read-outs of
specific functional or technical parameters, in other
cases they might require a highly detailed mechanistic
digital representation of the process. Digital tools can
be classified in a number of ways. One of them is ac-
cording to the in silico (modelling) technology they are
based on (see Figure 1, vertical), ranging from data
driven technologies (top) where only experimentally
generated information is used, to mechanistic model-
ling technologies (bottom) that have been developed
based on concepts and hypotheses informed by current
biological knowledge and insights. Mechanistic models
may be superior in providing insight into the system
under consideration, since their parameters have a
physical meaning. However, they have a significant costFigure 1
Schematic representation of the tissue engineering R&D process (horizontall
boxes illustrate the examples discussed in this paper: cellular regulation, mate
the light orange boxes (classical biomaterial design [5] & in silico clinical trials
overview. (For interpretation of the references to color/colour in this figure leg
www.sciencedirect.comof development, are more difficult to parameterise, and
are generally harder to compute in real-time, which is
often a requirement for Digital Twins. Furthermore, the
complexity of the biological processes is often too high,
or our understanding of the process is too limited, in
order to describe them by fully mechanistic models.
Because of their black-box nature, data-driven models
on the other hand provide less insight into the system,
but are more straightforward to develop, and in situa-
tions where the data logging surpasses the speed
of analysis they, provide an ideal basis for online pre-
diction and control [3]. In the field of regenerative
medicine, there is often abundant high-quality
manufacturing process data available (O2, pH etc.)
due to GMP requirements, which could be an advan-
tage for the data-driven approaches. Nevertheless,
doctors and regulators might be reluctant to use data-
driven models in clinical settings due to their black-
box nature. Additionally, results from a data-based
model can often not be extrapolated to cases outside
of the initial scope of the data. Ultimately, hybrid
strategies, resulting in the formation of a cross talk
and integration between data-based and mechanistic
models could provide an efficient framework to gain the
best of both worlds [4].y) and the computer model classification (vertically). The dark orange
riomics, bioreactor process quantification & cell expansion. Examples in
[6] are not discussed in this paper, but are mentioned to complete the
end, the reader is referred to the Web version of this article.)
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of a number of digital strategies developed in the field of
regenerative medicine linking straight into the concept
of the Digital Twin. We will discuss strategies, both
data-driven and mechanistic, some of which are mostly
confined to the research phase of the tissue engineering
pipeline whereas others that are mostly relevant in the
development phase (Fig. 1, horizontal). For the sake of
consistency and given the authors’ expertise, the spe-
cific examples discussed originate from the sub-field of
skeletal tissue engineering. However, some of the tools
are generic in terms of the biological applications,
whereas for other tools tissue-specific counterparts in
other organ systems also exist or are being developed.
The word “process” is used throughout the text in a
variety of meanings, referring to the biological process
(of cell proliferation, cell differentiation etc.), the
bioreactor process, the manufacturing process (all steps
leading up to the production of the TE product) or the
process of computer modelling (involving design,
implementation and validation).Examples
Starting at the bench side of the R&D pipeline, the first
example describes the use of a literature-derived
network model to gain more insight in the myriad in-
teractions governing the behaviour of a growth plate
chondrocyte. The following example discusses the use
of high-throughput material surface topography testing
devices with the appropriate digital tools to quantify and
interpret the results. A third example shows how
mechanistic models can help to quantify the microen-
vironment cells create for themselves during culture in a
perfusion bioreactor set-up while the last example dis-
cusses data-based digital tools that can be used to
monitor and control the bioreactor process itself.
Cellular regulation of the growth plate as a blueprint
for skeletal stem cell culture strategies
The specialization of cartilage cells, or chondrogenic
differentiation, is an intricate and meticulously regu-
lated biological process that plays a vital role in both
bone formation and cartilage regeneration. Under-
standing the molecular regulation of this process allows
optimizing cell culture and differentiation strategies
that are used in the context of skeletal tissue engi-
neering. The studies by Kerkhofs et al. [7e9] describe
the development of a network model of the growth plate
chondrocyte based on studies reported in the literature.
This literature-based network contains the major path-
ways active in the growth plate. In a first implementa-
tion, a Boolean modelling strategy was used where genes
can be either on or off, interactions amongst the genes
are described by Boolean operators and the notion of
time is completely absent [7]. Despite these simplifi-
cations, the model was able to capture the general
behaviour of the chondrocytes in the different layers ofCurrent Opinion in Biomedical Engineering 2018, 6:92–98the growth plate. Furthermore, the effects of various
knockouts on the growth place signalling and
morphology were accurately captured by the model.
In a follow-up study [8], the Boolean modelling strategy
was abandoned for an additive strategy, allowing genes to
take any value between 0 and 1 as well as having some
time resolution by making a distinction between fast
(post translational modification) and slow (transcrip-
tional) processes. These new features allowed capturing
the dose effect of certain growth factor actions. Subse-
quently, the model was used to perform an in silico
screening of the contribution of all of the modelled
factors towards the different chondrocyte phenotypes.
In other words, it allowed performing an in silico
screening of potential culture strategies for either
inducing hypertrophy or maintaining cells in a prolifer-
ative state [9]. Performing such an in silico screening step
allows to identify key candidates, which strongly
reduced the size and complexity of the experimental
screening effort.
To fine-tune the model, a genetic algorithm strategy was
used to find those combinations of model parameters
(presence and weight of the arrows connecting different
players in the network) that allowed capturing overall
growth plate expression profiles. Additionally, a variety
of network inference methods was used in a consensus
approach to infer a regulatory network from microarray
studies published in the literature. This consensus
network served to identify possible additions to the
network for which insufficient direct evidence was
available in the literature at the time of the construction
of the literature-derived network, and which might have
interesting therapeutic consequences.
A systems approach to the design of new
biomaterials
A systems approach as the one described in the previous
example is not only applicable to a pure biological
context, but also to the context of materials design, in a
field that has been baptized ‘materiomics’ [10]. Mate-
rials and their environments are approached as systems
that can be modelled and thus explored in silico. That
means going beyond the pure material screening to-
wards a more rational material discovery approach.
Given the size of the materiome to be explored, moving
from low-throughput to high-throughput should indeed
entail more than simply testing more materials at the
same time. The TopoChip [11] is an example of such a
high throughput screening platform where in silico tools
are used both in the design and the analysis of the
screening experiment.
In brief, surface topography has been observed to
significantly affect cell shape (roundness, nucleus size,
perimeter and orientation) [12], exerts mitogenicwww.sciencedirect.com
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the underlying mechanisms are only partially under-
stood. Using three types of primitive shapes, being tri-
angles, circles and rectangles, a library of topographies
was designed by varying the size, number and combi-
nation of primitives to be used. These topographies
were subsequently imprinted on polylactic acid chips
and seeded with cells in a static culture experiment.
The cellematerial interactions on the chip could be
quantified using a plethora of techniques from high-
throughput gene expression to imaging assays. For the
latter, automated high content imaging on the basis
specific fluorescent markers was the starting point of the
analysis, followed by the use of CellProfiler’s automatic
imaging pipeline for data quality check and segmenta-
tion. The resulting huge set of quantitative data was
mined using machine learning and computer modelling.
So far, analyses have revealed a spectrum of topographies
that induce various levels of cellular morphologies [11]
and topographies that stimulate proliferation and
induced pluripotent stem cell pluripotency [15].
3D neotissue growth modelling for understanding
and optimising bioreactor culture processes
Topography is not only important for the cells’ response
to the material surface, but also to the geometry of the
3D scaffold they are seeded on. 3D scaffold-based cell
growth for the formation of engineered tissues in
perfusion bioreactors is a highly complex process with
multiple parameters affecting the properties of the end
product. In order to be able to implement design prin-
ciples, in silico tools are required that able to capture and
subsequently steer such highly complex processes.
Briefly, scaffold topography parameters such as local
curvature can affect tissue growth [16] a phenomenon
attributed to the tensile forces that can be sensed by
cells in such locations [17]. In addition, tissue growth
kinetics can be influenced by flow related stresses as
well as concentrations of nutrients, growth factors, and
metabolic byproducts. Guyot et al. [18] used the level-
set method for simulating this curvature-dependent
growth of neotissue (cells and their extracellular
matrix) by tracking the evolution of the interface
between the neotissue and the void space on the
three-dimensional scaffold, and by using image based
strategies based on nanofocus Computed Tomography
technologies [19]. Through this initial in silico tool pre-
vious experimental findings [20] were confirmed,
showing the relevance of the model. In subsequent
studies, this model was extended to include the impact
of parameters associated with dynamic culture condi-
tions by incorporating the Brinkman equations govern-
ing the flow. This allowed quantifying fluid velocity and
shear stress profiles for both free flow and flow at the
tissue interface, but also within the tissue’s porous
domain [21]. This was a progress with respect to the
state of the art where shear stress calculations werewww.sciencedirect.comcarried out on empty scaffolds [22,23] or assuming
neotissue to be an impermeable volume without any
flow [24,25]. It also allowed whole scaffold volumes to
be captured and not only small a compartment of the
domain. The aforementioned approaches including cells
on the scaffold domain were sufficient for capturing the
initial stages of neotissue formation. However, they
were inadequate for capturing the later stages as the
growing neotissue is a porous tissue that allows flow
through its own micro-pores, thereby changing the local
flow environment as well as the mechanical (shear)
stimulation on the cells inside the neotissue, and
thereby ultimately affecting the neotissue growth itself.
Therefore, in a next modelling step, growth kinetics of
the in silico neotissue were coupled to the mechanical
factors [26] but also to the physicochemical factors
(unpublished Guyot) thus constituting a model that
could substantially aid in deciphering and subsequently
designing bioreactor processes.
The application of mechanistic models such as the one
described above can be hampered by their high-cost.
Although “accurate” information can be extracted, it
would not be possible to use them for investigating a
large process space. Hence model reduction strategies
have been also explored. Mehrian et al. [27], applied
model reduction by reformulating the neotissue growth
model discussed above from a set of partial differential
equations into a set of ordinary differential equations. By
following this approach, a homogenized model was ob-
tained that was 105 fold faster than the mechanistic 3D
version, which permitted the application of rigorous
optimization techniques such as Bayesian optimization.
This allowed a “high throughput” in silico screening that
determined global optima for the medium refreshment
strategies in terms of frequency and percentage of
medium replaced, leading to maximized neotissue
growth kinetics in the perfusion bioreactor set-up under
study.
On-line monitoring techniques for critical quality
attributes of cells
For cell therapy bioreactors, in general, it is common
that on-line measurements of physicochemical variables
(e.g. pH, O2) are used to control the environmental
conditions. However it is more challenging to obtain on-
line and non-invasive information directly on the critical
quality attributes (CQAs) of the cells themselves. Even
more challenging is to use this information to directly
control the CQAs of the cultured cells, e.g. their growth
characteristics, metabolic state, and ultimately in vivo
potency. As more process data is collected and the effect
of the microenvironment on the cells is better under-
stood, it is a promising approach to estimate the un-
measurable CQAs in real-time, based on (a combination
of) indirect measurements that can be related to the
CQA of interest. This strategy, where the information ofCurrent Opinion in Biomedical Engineering 2018, 6:92–98
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interpretable process parameters is generally known as a
‘soft sensor’ method [28,29]. Ultimately this ‘model-
based monitoring’ strategy, if combined with a desired
output trajectory of the CQA, can be used as the basis
for ‘model-based control’ in which the measured process
data and a model are used to determine the most
appropriate controller setting to reach the desired state
of the process or the cells. More often used in fermenter
bioreactors [30e33], only limited examples of model-
based control can be found in literature for stem cell
bioreactors [34]. An example of model-based predictive
monitoring can be found in Ref. [35] where a data-
driven model based on real-time imaging data from a
bioreactor’s harvest process was able to link the on-line
monitored feature variable (cell circularity) to a process
decision (‘stop the enzymatic harvest reaction’). The
online monitoring and data-analysis allowed even to
predict when to stop the cell harvesting process, while
the process was still ongoing (i.e. making the monitoring
faster than real-time). The data-driven monitoring
method used in this application is useful to optimise the
incubation time for cell harvests in planar culture sys-
tems for different donors or different harvest solutions.
Another example of this data-based modelling, this time
in a perfusion bioreactor, can be found in Ref. [36],
where a purely data-driven transfer function model was
used to relate dynamics in oxygen measurements to
estimations on the number of cells present in the
bioreactor. However, this data-driven model might not
be applicable outside of the scope for which it was
originally developed. Therefore, in order to corroborate
the results of the data-driven model, the steady state
gain of the transfer function was linked to the dynamics
in the oxygen data by means of a simple mechanistic
oxygen consumption model. Another hybrid modelling
strategy could be to start from the mechanistic model
and perform a model reduction step, followed by a re-
parametrisation based on available experimental data,
as has been described in the previous section [27].
Similar approaches based on this online data-based
monitoring and control strategy pose tremendous po-
tential if one would have access to online readouts of
biomarkers that make up the biological signature of a
cellular state and therefore enable the control of in vivo
cell potency in vitro.Discussion
When developing and using digital technologies for
biomedical applications, there are a number of consid-
erations to be made regarding various steps of the
modelling process. Data collection and validation are
two extremely important steps that are currently the
subject of intense efforts within the community.
Furthermore, interoperability, cloud computing &
infrastructure and the implications of the General Data
Protection Regulation (GDPR) and open scienceCurrent Opinion in Biomedical Engineering 2018, 6:92–98initiatives are important to consider but their discussion
is beyond the scope of this paper.
Data collection
A major prerequisite for in silico models is the access to
large amounts of qualitative data, either to construct the
data-driven models or to validate the mechanistic
models. Data platform initiatives could help to collect
structured data for the development of in silico models.
In R&D settings (towards the bench side of Fig. 1) often
experimental data is still collected with respect to one
specific experimental variable. This one-factor-at-a-
time approach yields data for models with a very
limited scope. More recently, by virtue of the quality-by-
design (QbD) principles that are becoming mainstream
in regenerative medicine development [37], data
collection taking the whole design space into account by
a Design of Experiment (DoE) approach yield much
richer datasets. Subsequently, the resulting models are
often able to describe the biological processes more
realistically. Since well characterized experimental re-
sults could serve multiple modelling purposes, data
platform initiatives such as the compendium for
Biomaterial Transcriptomics (cBiT) for materials design
[38] could reduce the effort of model development and
validation significantly.
Closer to the bedside, in the regulated environment of
regenerative medicine applications, large amounts of
data are being collected, for example to comply to Good
Manufacturing Practices (GMP). While currently this
data is generally primarily collected for regulatory
purposes, they contain a wealth of information for in
silico models. However, often the data structure and
medium (i.e. paper formats) in a GMP setting are not
always ideal for modelling purposes. Additionally the
labour cost of acquiring, or even logging, additional data
in a GMP setting is very high. Processes with on-line in-
process controls are therefore not only beneficial for
the product quality, but also as a basis to develop in silico
models. With the upcoming Internet-of-Things tech-
nology, the efficient and regulatory compliant (e.g. 21
CFR part 11 [39] and EU GMP Annex 11 [40])
collection and subsequent analysis of this data becomes
more important. Again, data platform initiatives do
exist that try to consolidate the (pre-) clinical data
streams in regenerative medicine (e.g. MyCellHub,
Trakcel, Vineti,.).
Model validation
In silico models can be (and already are)- part of dossiers
that are submitted to the regulator, either in the form of
evidence obtained from in silico modelling or in the form
of software that is an integral part of the device that
needs to be regulated. This requires the sponsors to
demonstrate the credibility of their in silico tools. The
first step in building this credibility is documentation ofwww.sciencedirect.com
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Drug Administration (FDA) has published a clear
guidance [41] explaining what technical information
needs to be communicated when submitting (the re-
sults of) a digital tool. The next step is the VVUQ -
verification, validation and uncertainty quantification.
Whereas verification refers to the correspondence be-
tween the simulation outcome and the underlying
mathematical equations, validation refers to the corre-
spondence between the simulation results and the real-
world observations. In a joint effort between the FDA
and the ASME (American Society of Mechanical Engi-
neers), guidelines are being formulated in the form of a
verification & validation standard for medical devices
(V&V40), in imitation of the V&V’s that have been
developed for in silico products from the automotive and
aerospace industry. Uncertainty Quantification looks at
how the uncertainties on the model inputs and as-
sumptions effect the simulation results. A last step in
the credibility building process is the applicability
analysis, looking at the relevance of the computer model
and its validation evidence to the proposed context of
use [42]. Even though most of the concepts mentioned
in this overview have been applied primarily to medical
devices and, to a lesser extent, to drugs, the same
strategy applies to advanced therapy products (ATMP).Summary and outlook
One of the key elements of the Industry 4.0 initiative
lies the vision of a digital transformation of
manufacturing (i.e. the Digital Twin), especially when
high value products come in play such as in the case of
tissue engineering. For example, the implementation of
“smart” self-regulated factories, able to guide cellular
transformations and ATMP assembly using feedback
signals can only become a reality by the adoption of in
silico elements for monitoring and control. Subsequently,
the ability to systematically and rigorously optimize
tissue engineering processes using in silico tools can allow
process intensification and drive production footprint to
a minimum, an element which is highly necessary for
costly GMP-grade AMTP manufacturing. From initial
cell culture, biomaterial development and process
design, model-based approaches should be adopted to
minimize risk and cost of ATMP development. With the
adoption of novel automated downstream units of
operation adapted for use in the cell therapy and
regenerative medicine field, digitised process integra-
tion and whole process self-regulation can become a
reality. Tissue engineering could thereby become a
major industrial example where the industry 4.0 vision
and the incorporation of the Digital Twin concept be-
comes not just an improvement, but a necessity.
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